CDCA4 as a novel molecular biomarker of poor prognosis in patients with lung adenocarcinoma
Sign Up to like & getrecommendations! Published in 2022 at "Frontiers in Oncology"
DOI: 10.3389/fonc.2022.865756
Abstract: Background Because of the high incidence and poor prognoses of lung adenocarcinoma (LUAD), it is essential to identify cost-effective treatment options and accurate and reliable prognostic biomarkers. CDCA4 upregulation has been identified in many cancers.… read more here.
Keywords: lung adenocarcinoma; biomarker; cdca4 expression; cdca4 novel ... See more keywords